Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer

39Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

Anterior gradient 2 (AGR2) is a gene predominantly expressed in mucus-secreting tissues or in endocrine cells. Its expression is drastically increased in tumors including prostate cancer. Here we investigated whether AGR2 transcript levels can be used as a biomarker to detect prostate cancer (PCa). Using a PCR-based approach, we could show that in addition to the wild-type (AGRwt long and short) transcripts, five other AGR2 splice variants (SV) (referred to as AGR2 SV-C, -E, -F, -G and -H) were present in cancer cell lines. In tissue biopsies, SV-H and AGR2wt (short) distinguished between benign and PCa (p ≤ 0.05 n = 32). In urine exosomes, AGR2 SV-G and SV-H outperformed serum PSA. Receiver operating characteristic (ROC) curves showed the highest discriminatory power of SV-G and SV-H in predicting PCa. AGR2 SV-G and SV-H are potential diagnostic biomarkers for the non-invasive detection of PCa using urine exosomes.

Cite

CITATION STYLE

APA

Neeb, A., Hefele, S., Bormann, S., Parson, W., Adams, F., Wolf, P., … Cato, A. C. B. (2014). Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. Oncotarget, 5(18), 8681–8689. https://doi.org/10.18632/oncotarget.2365

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free